Genenta Science (GNTA) News Today → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free GNTA Stock Alerts $2.90 -0.01 (-0.34%) (As of 09:33 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinemarketbeat.com - April 24 at 11:26 AMGenenta Science SpA Sponsored ADRcnn.com - April 11 at 11:47 AMBioVie stock plunges 43% following public offering pricingmsn.com - March 4 at 1:19 PMmarketbeat.com - February 20 at 9:51 AMBuy Rating for Genenta Science SpA on Strong Clinical Prospects and Innovative Gene Therapy Platformmarkets.businessinsider.com - February 10 at 7:52 AMGenenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumorsfinance.yahoo.com - February 8 at 11:04 AMIs Genenta Science (NASDAQ:GNTA) In A Good Position To Invest In Growth?finance.yahoo.com - February 3 at 7:49 AMGenenta Science (NASDAQ:GNTA) Stock Price Down 7.2%marketbeat.com - February 3 at 2:31 AMmarketbeat.com - November 22 at 11:35 AMIndividual investors account for 54% of Genenta Science S.p.A.'s (NASDAQ:GNTA) ownership, while insiders account for 30%finance.yahoo.com - November 14 at 10:14 AMGenenta Science S.p.A. (GNTA)au.finance.yahoo.com - August 18 at 2:54 AMGenenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatmentsfinance.yahoo.com - July 28 at 10:26 AMmarketbeat.com - July 13 at 12:29 PMHere's Why We're Not Too Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn Situationfinance.yahoo.com - July 8 at 3:10 PMGENENTA SCIENCE SPA: The European Commission Grants Orphan Drug Designation to Temferon for Treatment of Gliomafinanznachrichten.de - June 29 at 12:38 PMThe European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Gliomafinance.yahoo.com - June 29 at 7:37 AMInsiders own 30% of Genenta Science S.p.A. (NASDAQ:GNTA) shares but individual investors control 59% of the companyfinance.yahoo.com - May 17 at 10:35 AMGenenta to Provide Update on Lead Product Temferon™finance.yahoo.com - May 16 at 9:26 AMFY2023 Earnings Estimate for Genenta Science S.p.A. Issued By HC Wainwright (NASDAQ:GNTA)marketbeat.com - May 1 at 3:35 AMHC Wainwright Comments on Genenta Science S.p.A.'s FY2027 Earnings (NASDAQ:GNTA)marketbeat.com - April 28 at 9:05 AMGENENTA SCIENCE SPA: Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filingfinanznachrichten.de - April 26 at 8:54 AMGenenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filingfinance.yahoo.com - April 26 at 8:54 AMGenenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indicationsfinance.yahoo.com - April 3 at 10:16 AMGenenta Gets FDA Orphan-Drug Designation for Temferon in Glioblastoma Multiforme >GNTAmarketwatch.com - March 2 at 9:32 AMFDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiformefinance.yahoo.com - March 2 at 9:32 AMGenenta Science S.p.A. ADRwsj.com - February 24 at 3:38 PMH.C. Wainwright Keeps Their Buy Rating on Genenta Science SpA Sponsored ADR (GNTA)markets.businessinsider.com - February 8 at 7:50 AMGenenta Science and AGC Biologics Enter Development and Manufacturing Service Agreementfinance.yahoo.com - February 7 at 10:41 AMWe Think Genenta Science (NASDAQ:GNTA) Can Easily Afford To Drive Business Growthfinance.yahoo.com - January 29 at 9:21 AMGenenta Science S.p.A. (NASDAQ:GNTA) most popular amongst individual investors who own 60%, insiders hold 29%finance.yahoo.com - December 8 at 7:12 AMGenenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patientsfinance.yahoo.com - November 7 at 10:35 AMGenenta Provides First Half 2022 Business Update and Financial Resultsfinance.yahoo.com - October 24 at 10:06 AMGenenta to Present at Upcoming Scientific and Investor Conferencesfinance.yahoo.com - October 5 at 10:27 AMGenenta to Present at Upcoming Investor Conferencesfinance.yahoo.com - September 7 at 8:27 AMWe're Not Very Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn Ratefinance.yahoo.com - August 22 at 8:36 AMmarketbeat.com - July 29 at 9:30 AMThis Small Cap Cancer Company 'Hijacks Tumors From Within," HC Wainwright Saysuk.investing.com - July 27 at 10:13 AMGene therapy developer Genenta Science named a buy at Wainwright on tumor approachseekingalpha.com - July 27 at 10:13 AMAmCham Italy and Genenta Science Announce the Bowling Green Bull Initiativefinance.yahoo.com - July 25 at 9:33 AMAmCham Italy and Genenta Science Announce the Bowling Green Bull Initiativefinance.yahoo.com - July 25 at 9:33 AMGenenta Science on track and well financed to begin phase II trial in 2023proactiveinvestors.com.au - July 14 at 9:52 PMmarketbeat.com - June 28 at 10:07 AMmarketbeat.com - June 28 at 9:37 AMmarketbeat.com - June 23 at 3:42 PMWhat Kind Of Investors Own Most Of Genenta Science S.p.A. (NASDAQ:GNTA)?finance.yahoo.com - May 27 at 9:58 AMGenenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHAfinance.yahoo.com - May 13 at 5:02 PMmarketbeat.com - May 10 at 9:56 AMGenenta Appoints Industry Veteran Tim Obara as Head of Business Developmentfinance.yahoo.com - May 9 at 8:58 AMGenenta Files Annual Report on Form 20-F for Fiscal Year 2021finance.yahoo.com - May 4 at 6:09 PMGenenta Progresses to Higher Dosing Cohort in Temferon(TM) Phase 1/2a Clinical Trial in Glioblastoma Multiformestockhouse.com - May 4 at 12:51 PM Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address The Hard Truth About Investing For Retirement (Ad)Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading. Click To Access This Powerful Training Right Now! GNTA Media Mentions By Week GNTA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNTA News Sentiment▼-0.500.34▲Average Medical News Sentiment GNTA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNTA Articles This Week▼20▲GNTA Articles Average Week Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Aligos Therapeutics News Today Ikena Oncology News Today Turnstone Biologics News Today Entera Bio News Today Cidara Therapeutics News Today Instil Bio News Today Elutia News Today Semper Paratus Acquisition News Today Dyadic International News Today Cognition Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GNTA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
